File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Randomized controlled trial of vitamin D supplement on endothelial function in patients with type 2 diabetes

TitleRandomized controlled trial of vitamin D supplement on endothelial function in patients with type 2 diabetes
Authors
KeywordsEndothelial function
Type 2 diabetes mellitus
Vitamin D
Issue Date2013
PublisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/atherosclerosis
Citation
Atherosclerosis, 2013, v. 227 n. 1, p. 140-146 How to Cite?
AbstractBackground: Suboptimal vitamin D status is associated with endothelial dysfunction and an increased risk of cardiovascular diseases but it is unclear whether vitamin D supplementation is beneficial. The aim was to investigate the effect of vitamin D supplementation on endothelial function in patients with type 2 diabetes mellitus (DM). Methods: In a double-blind, placebo-controlled trial, we randomized 100 type 2 DM patients to vitamin D supplement (5000 IU/day, n = 50) or placebo (controls, n = 50) for 12 weeks. Assessment of vascular function with brachial artery flow-mediated dilatation (FMD), circulating levels of endothelial progenitor cells (EPCs) and brachial-ankle pulse wave velocity, and metabolic parameter, high-sensitivity C-reactive protein (hsCRP) and oxidative stress markers were performed before and after the supplementation. Results: After 12 weeks, vitamin D treated patients had significant increases in serum 25-hydroxyvitamin D [25(OH)D] concentration (treatment effect 34.7 ng/mL, 95% CI 26.4–42.9, P < 0.001) and serum ionized calcium (treatment effect 0.037 mmol/L, 95% CI 0.007–0.067, P = 0.018); decreased serum parathyroid hormone concentration (treatment effect −0.55 pmol/L, 95% CI −1.08 to −0.02, P = 0.042) compared to patients who received placebo. Nevertheless, vitamin D supplementation did not improve vascular function as determined by FMD, circulating EPC count or baPWV (all P > 0.05). Furthermore, hsCRP, oxidative stress markers, low- and high-density lipoprotein and glycated hemoglobin were also similar between two groups (all P > 0.05). Conclusion: In patients with type 2 DM, 12 weeks oral supplementation of vitamin D did not significantly affect vascular function or serum biomarkers of inflammation and oxidative stress. Clinical trial number: HKCTR-867, www.hkclinicaltrials.com.
Persistent Identifierhttp://hdl.handle.net/10722/182005
ISSN
2021 Impact Factor: 6.847
2020 SCImago Journal Rankings: 1.554
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorYiu, YFen_US
dc.contributor.authorYiu, KHen_US
dc.contributor.authorSiu, DCWen_US
dc.contributor.authorChan, YHen_US
dc.contributor.authorLi, SWen_US
dc.contributor.authorWong, LYen_US
dc.contributor.authorLee, SWen_US
dc.contributor.authorTam, Sen_US
dc.contributor.authorWong, EWen_US
dc.contributor.authorLau, CPen_US
dc.contributor.authorCheung, BMYen_US
dc.contributor.authorTse, HFen_US
dc.date.accessioned2013-04-17T07:17:08Z-
dc.date.available2013-04-17T07:17:08Z-
dc.date.issued2013en_US
dc.identifier.citationAtherosclerosis, 2013, v. 227 n. 1, p. 140-146en_US
dc.identifier.issn0021-9150en_US
dc.identifier.urihttp://hdl.handle.net/10722/182005-
dc.description.abstractBackground: Suboptimal vitamin D status is associated with endothelial dysfunction and an increased risk of cardiovascular diseases but it is unclear whether vitamin D supplementation is beneficial. The aim was to investigate the effect of vitamin D supplementation on endothelial function in patients with type 2 diabetes mellitus (DM). Methods: In a double-blind, placebo-controlled trial, we randomized 100 type 2 DM patients to vitamin D supplement (5000 IU/day, n = 50) or placebo (controls, n = 50) for 12 weeks. Assessment of vascular function with brachial artery flow-mediated dilatation (FMD), circulating levels of endothelial progenitor cells (EPCs) and brachial-ankle pulse wave velocity, and metabolic parameter, high-sensitivity C-reactive protein (hsCRP) and oxidative stress markers were performed before and after the supplementation. Results: After 12 weeks, vitamin D treated patients had significant increases in serum 25-hydroxyvitamin D [25(OH)D] concentration (treatment effect 34.7 ng/mL, 95% CI 26.4–42.9, P < 0.001) and serum ionized calcium (treatment effect 0.037 mmol/L, 95% CI 0.007–0.067, P = 0.018); decreased serum parathyroid hormone concentration (treatment effect −0.55 pmol/L, 95% CI −1.08 to −0.02, P = 0.042) compared to patients who received placebo. Nevertheless, vitamin D supplementation did not improve vascular function as determined by FMD, circulating EPC count or baPWV (all P > 0.05). Furthermore, hsCRP, oxidative stress markers, low- and high-density lipoprotein and glycated hemoglobin were also similar between two groups (all P > 0.05). Conclusion: In patients with type 2 DM, 12 weeks oral supplementation of vitamin D did not significantly affect vascular function or serum biomarkers of inflammation and oxidative stress. Clinical trial number: HKCTR-867, www.hkclinicaltrials.com.-
dc.languageengen_US
dc.publisherElsevier Ireland Ltd. The Journal's web site is located at http://www.elsevier.com/locate/atherosclerosisen_US
dc.relation.ispartofAtherosclerosisen_US
dc.subjectEndothelial function-
dc.subjectType 2 diabetes mellitus-
dc.subjectVitamin D-
dc.titleRandomized controlled trial of vitamin D supplement on endothelial function in patients with type 2 diabetesen_US
dc.typeArticleen_US
dc.identifier.emailYiu, KH: khkyiu@hku.hken_US
dc.identifier.emailSiu, DCW: cwdsiu@hkucc.hku.hken_US
dc.identifier.emailWong, LY: navywong@hkucc.hku.hken_US
dc.identifier.emailLau, CP: cplau@hku.hken_US
dc.identifier.emailCheung, BMY: mycheung@hku.hken_US
dc.identifier.emailTse, HF: hftse@hkucc.hku.hken_US
dc.identifier.authorityYiu, KH=rp01490en_US
dc.identifier.authoritySiu, DCW=rp00534en_US
dc.identifier.authorityCheung, BMY=rp01321en_US
dc.identifier.authorityTse, HF=rp00428en_US
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.atherosclerosis.2012.12.013-
dc.identifier.pmid23298824-
dc.identifier.scopuseid_2-s2.0-84873473168-
dc.identifier.hkuros214028en_US
dc.identifier.volume227en_US
dc.identifier.issue1en_US
dc.identifier.spage140en_US
dc.identifier.epage146en_US
dc.identifier.isiWOS:000314785400023-
dc.identifier.issnl0021-9150-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats